

Unless otherwise defined herein, the capitalised terms used in this announcement have the same meaning as those used in the Company's announcements released on 13 February 2025.

17 February 2025

Physiomics plc

("Physiomics" or the "Company")

Result of WRAP Retail Offer

Physiomics plc (AIM: PYC), is pleased to announce, further to the announcements made on 13 February 2025, the completion of the WRAP Retail Offer, at the same price as the previously announced Placing (together the **Fundraise**). The WRAP Retail Offer, which closed at 11 a.m. today, has raised aggregate gross proceeds of £70,000 through the issue of a total of 14,000,000 new Ordinary Shares, alongside the previously announced Placing of £430,000. The WRAP Retail Offer was slightly oversubscribed and was therefore subject to a small scale back.

The Fundraise, which is conditional on Admission, raised gross proceeds of, in aggregate, £500,000, via the issue of 86,000,000 Placing Shares pursuant to the Placing and 14,000,000 WRAP Retail Offer Shares pursuant to the WRAP Retail Offer.

Use of Proceeds

In order to further develop its business and accelerate growth, the Company is raising funds to carry out the following activities and for general working capital:

- Mathematical Modelling Consulting Service
 - Recruitment of further technical team members to accelerate the conversion of the pipeline and support service delivery;
 - Investment in Business Development and Marketing to build and strengthen the pipeline, expand into new therapeutic areas, further develop its data science offering and refresh messaging; and
 - Explore strategic options to accelerate the growth of modelling services.
- Biostatistics Consulting Service
 - Organic growth of the service through Business Development and Marketing to acquire clients; and
 - Explore strategic options to accelerate the growth of biostatistics services.
- Personalised Medicine Tool Development
 - Explore a deeper relationship with DoseMe to develop models to be implemented on their platform; and
 - Implementation of the Company's current personalised dosing tool on the DoseMeRx Platform enabling it to be made available to clinicians across the US.

Admission and Total Voting Rights

Applications have been made for the Placing Shares and the WRAP Retail Offer Shares to be admitted to trading on AIM, which is expected to become effective and dealings commence on or around 8.00 a.m. on 18 February 2025 ("**Admission**").

Following Admission, the Company's issued ordinary share capital will consist of 303,208,718 Ordinary Shares. Since the Company currently holds no Ordinary Shares in treasury, the total voting rights in the Company will be 303,208,718. These figures may be used by shareholders of the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

The new Ordinary Shares to be issued pursuant to the WRAP Retail Offer will be issued free of all liens, charges and encumbrances and will, on Admission, rank *pari passu* in all respects with the new Ordinary Shares to be issued pursuant to the Placing and the Company's existing Ordinary Shares.

For further information, please contact:

Physiomics plc	+44 (0) 1235 841575
Dr Peter Sargent, CEO	

Hybridan LLP (Broker)	+44 (0) 203 764 2341
Claire Louise Noyce	

Strand Hanson Limited (NOMAD)	+44 (0) 20 7409 3494
James Dance & James Bellman	

Winterflood Retail Access Platform	WRAP@winterflood.com
Joe Winkley, Sophia Bechev	+44 (0)20 8100 0000

Further information on the Company can be found on its website at www.physiomics.co.uk

The Company's LEI is 213800A71DSZ6ABMTQ91.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

ROIPKOBPBBKDABD